WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012050365) BIOMARKER FOR DIAGNOSING GLIOBLASTOMA OR PREDICTING PROGNOSIS OF GLIOBLASTOMA PATIENTS, AND USE THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/050365    International Application No.:    PCT/KR2011/007592
Publication Date: 19.04.2012 International Filing Date: 12.10.2011
IPC:
C12Q 1/68 (2006.01), G01N 33/68 (2006.01)
Applicants: SAMSUNG LIFE PUBLIC WELFARE FOUNDATION [KR/KR]; 742-3, Hannam-dong Yongsan-gu Seoul 140-893 (KR) (For All Designated States Except US).
NAM, Do Hyun [KR/KR]; (KR) (For US Only).
KIM, Jong Hyun [KR/KR]; (KR) (For US Only).
PARK, Kwan [KR/KR]; (KR) (For US Only).
SHIN, Hyung Jin [KR/KR]; (KR) (For US Only).
HONG, Seung Chyul [KR/KR]; (KR) (For US Only).
LEE, Jung-il [KR/KR]; (KR) (For US Only).
KONG, Doo-Sik [KR/KR]; (KR) (For US Only).
SEOL, Ho Jun [KR/KR]; (KR) (For US Only).
SUH, Yeon-Lim [KR/KR]; (KR) (For US Only)
Inventors: NAM, Do Hyun; (KR).
KIM, Jong Hyun; (KR).
PARK, Kwan; (KR).
SHIN, Hyung Jin; (KR).
HONG, Seung Chyul; (KR).
LEE, Jung-il; (KR).
KONG, Doo-Sik; (KR).
SEOL, Ho Jun; (KR).
SUH, Yeon-Lim; (KR)
Agent: LEE, Cheo Young; 11F., Yeosam Bldg. 648-23, Yeoksam-dong, Gangnam-gu Seoul 135-080 (KR)
Priority Data:
10-2010-0100050 13.10.2010 KR
Title (EN) BIOMARKER FOR DIAGNOSING GLIOBLASTOMA OR PREDICTING PROGNOSIS OF GLIOBLASTOMA PATIENTS, AND USE THEREOF
(FR) MARQUEUR BIOLOGIQUE POUR DIAGNOSTIQUER UN GLIOBLASTOME OU PRÉVOIR LE PRONOSTIC DE PATIENTS SOUFFRANT D'UN GLIOBLASTOME, ET SON UTILISATION
(KO) 교모세포종의 진단 또는 예후 예측용 바이오 마커 및 그 용도
Abstract: front page image
(EN)The present invention relates to a biomarker for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients, and a use thereof, and more specifically, to an analysis method of a protein comprising the step of measuring the expression amount of the protein to provide the information necessary for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients by utilizing a protein selected from the group consisting of survivin, cyclinE, DCC, TGF-β, CDC25B, Histone H1, p-EGFR, p-VEGFR2/3 and p16 as a biomarker for diagnosing glioblastoma or predicting the prognosis of glioblastoma patients. Since the proteins discovered through the analysis of the present invention can be applied to predict the prognosis of glioblastoma patients, a kit can be provided for predicting the prognosis of glioblastoma patients using the same and to apply the discovered proteins to develop a novel target therapy with respect to the proteins and an anticancer drug. As a result, the biomarker would also have a great ripple effect on the related industry fields, and is thus useful.
(FR)La présente invention concerne un marqueur biologique pour diagnostiquer un glioblastome ou prévoir le pronostic de patients souffrant d'un glioblastome, et son utilisation, et plus spécifiquement, un procédé d'analyse d'une protéine comprenant l'étape de mesure de la quantité d'expression de la protéine pour obtenir l'information nécessaire pour diagnostiquer un glioblastome ou prévoir le pronostic de patients souffrant d'un glioblastome, en utilisant une protéine choisie dans l'ensemble consistant en survivine, cycline E, DCC, TGF-β, CDC25B, Histone H1, p-EGFR, p-VEGFR2/3 et p16 comme marqueur biologique pour diagnostiquer un glioblastome ou prévoir le pronostic de patients souffrant d'un glioblastome. Les protéines découvertes par l'analyse de la présente invention pouvant être appliquées pour prévoir le pronostic de patients souffrant d'un glioblastome, un kit peut être fourni pour prévoir le pronostic de patients souffrant d'un glioblastome en l'employant et pour appliquer les protéines découvertes au développement d'une nouvelle thérapie ciblée impliquant les protéines et d'un médicament anticancéreux. Ainsi, le marqueur biologique aura un effet de propagation sur les domaines industriels concernés et est donc utile.
(KO)본 발명은 교모세포종의 진단 또는 예후 예측을 위한 바이오 마커 및 그 용도에 관한 것으로, 더욱 자세하게는 survivin, cyclinE, DCC, TGF-β, CDC25B, Histone H1, p-EGFR, p-VEGFR2/3 및 p16 로 구성된 군에서 선택되는 단백질을 교모세포종의 진단 또는 예후 예측을 위한 바이오 마커로 활용하여, 교모세포종의 진단 또는 예후 예측에 필요한 정보를 제공하기 위해 상기 단백질의 발현량을 측정하는 단계를 포함하는 단백질의 분석방법에 관한 것이다. 본 발명의 분석을 통해 발굴된 단백질들은 교모세포종 환자의 예후 예측에 적용가능 함으로 이를 이용한 교모세포종 예후 진단용 키트를 제공할 수 있고, 발굴된 단백질들을 대상으로 한 새로운 개념의 표적 치료법 및 항암제 개발에 응용될 수 있어 유용하다. 또한, 이에 따라 관련 산업 분야에 큰 파급효과를 가져올 수 있어 유용하다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)